Horizon Pharma plc Announces Expansion and Relocation of U.S. Corporate Headquarters

DUBLIN, IRELAND--(Marketwired - Oct 5, 2015) - Horizon Pharma plc (NASDAQ: HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, announced today that it is expanding and relocating its U.S. corporate headquarters from Deerfield, Ill. to Lake Forest, Ill., with the signing of a long-term sublease for its new office space at 150 South Saunders Road.

The new office space is approximately triple the size of the current U.S. headquarters and can accommodate nearly 600 employees. Horizon Pharma will occupy the first through fourth floors of the 160,000-square-foot building. The expansion and relocation is expected to be completed in January 2016.

"Horizon has come a long way in eight years -- from one employee working in a coffee shop -- to more than 700 global employees," said Timothy P. Walbert, chairman, president and chief executive officer, Horizon Pharma plc. "In the last year alone, we have added nearly 100 employees in our U.S. headquarters and have experienced tremendous growth in the business overall. With this progress, as well as planning for future expansion, we needed to increase our physical space. Our new U.S. headquarters will provide us room to continue on this growth trajectory, and ultimately, to serve more patients."

"The City of Lake Forest is pleased to welcome Horizon Pharma, a rapidly growing biopharmaceutical company, and its current and future employees to the community," said Mayor Donald Schoenheider. "Horizon Pharma joins other corporate headquarters in the Route 60 Corridor, at the western gateway to the City. As a community, we look forward to building a long-term relationship with Horizon Pharma. We are excited to see ongoing interest and enhancement of the City's premier corporate office area. Lake Forest is a great place to do business."

About Horizon Pharma plc
Horizon Pharma plc is a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. The Company markets seven medicines through its orphan, primary care and specialty business units. Horizon's global headquarters are in Dublin, Ireland. For more information, please visit www.horizonpharma.com. Follow @HZNPplc on Twitter or view careers on our LinkedIn page.

Forward-Looking Statements
This press release contains forward-looking statements, including, but not limited to, statements related to the timing of Horizon Pharma's relocation of its U.S. corporate headquarters, the potential benefits of the new U.S. corporate headquarters, potential future growth of Horizon Pharma's business and employee base, and other statements that are not historical facts. These forward-looking statements are based on Horizon Pharma's current expectations and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks related to Horizon Pharma's ability to grow sales and revenues from existing products; the availability of coverage and adequate reimbursement and pricing from government and third party payers and risks relating to the success of Horizon Pharma's Prescriptions-Made-Easy or PME specialty pharmacy program; competition, including potential generic competition; the ability to protect intellectual property and defend patents; regulatory obligations and oversight; Horizon Pharma's ability to complete the planned relocation of its U.S. corporate headquarters on anticipated timelines, whether the new facilities will be adequate for Horizon Pharma's future needs, and those risks detailed from time-to-time under the caption "Risk Factors" and elsewhere in Horizon's filings and reports with the U.S. Securities and Exchange Commission. Horizon Pharma undertakes no duty or obligation to update any forward-looking statements contained in this presentation as a result of new information.